Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025
Provided By GlobeNewswire
Last update: Mar 10, 2025
PRT3789 has demonstrated clinical proof-of-concept that selectively degrading SMARCA2 is generally safe and has monotherapy anti-tumor activity in patients with SMARCA4-deficient, non-small cell lung (NSCLC), gastric and esophageal cancer
Read more at globenewswire.com
